Biosimilar Patent Strategy: Follow-Ons May Target Secondary, Third Party Patents
This article was originally published in The Pink Sheet Daily
Executive Summary
Initial applicants could establish solid precedents in courts and at FDA – to the benefit of subsequent competitors.